Antiglutamate therapy of ALS — which is the next step?
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which was thought to be untreatable for a long time. However, recent evidence in men indicates that antiglutamatergic strategies are the first to have an influence on its pathogenesis and slow down the disease process. Since the effect of the drugs is still small, this progress cannot only be seen as a success of the present but most also be acknowledged as a starting point for the future. How will these future studies look like? They will have to take into account that ALS presumably has a long preclinical period and they will use a number of novel compounds and treatment strategies which have recently been shown to be effective in a transgenic animal model. This also implies that we are likely to use combination therapies and have to try to treat patients early. The latter will be necessarily connected with the demand for a novel clinical attitude to the diagnosis of the disease.
KeywordsAmyotrophic Lateral Sclerosis Motor Neuron Excitatory Amino Acid Motor Neuron Disease Hereditary Spastic Paraplegia
Unable to display preview. Download preview PDF.
- Block W, Karitzky J, Traber F, Pohl C, Keller E, Mundegar RR, Lamerichs R, Rink H, Ries F, Schild HH, Jerusalem F (1998) Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease. Sub-group analysis and follow-up measurements. Arch Neurol 55: 931–936.PubMedCrossRefGoogle Scholar
- Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: 327–338.PubMedCrossRefGoogle Scholar
- Charcot JM (1974) Lecons sur les maladies du systéme nerveux faites à la Salpetrière. Paris. Progrès Medical 213-242.Google Scholar
- Dal Canto MC, Gurney ME (1994) Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 145: 1271–1279.Google Scholar
- Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47 [Suppl 4]: 233–241.Google Scholar
- Doble A (1997) Effects of riluzole on glutamatergic neurotransmission in the mammalian central nervous system, and other pharmacological effects. Rev Contemp Pharmacother 8: 213–225.Google Scholar
- Friedländer RM, Brown RH, Gagliardini V, Wang J, Yuan J (1997) Inhibition of ICE slows ALS in mice. Science 388: 31.Google Scholar
- 5Ludolph AC, Riepe MW (1999) Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic laterals sclerosis? Against, in press.Google Scholar
- Meyer T, Münch C, Völkel H, Booms P, Ludolph AC (1998b) The EAAT 2 (GLT-1) gene in motor neuron disease: Absence of mutations in amyotrophic lateral sclerosis and a point mutation in individuals with hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry, in press.Google Scholar
- Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA, the WALS Study Group (1996) Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 47: 1383–1388.PubMedGoogle Scholar
- Ochs G, Penn RD, Beck M, Giess R, Magnus T, Sims T, Sendtner M, Toyka KV (1998) Intrathecal infusion of recombinant human-brain-derived neurotrophic factor (rhBDNF) is well tolerated in patients with ALS. Abstract, 9th International Symposium on ALS/MND.Google Scholar
- Taylor CP (1995) Gabapentin — mechanisms of action. In: Levy RH, Mattson RH, Meldrum BNM (eds) Antiepileptic drugs, 4th ed. Raven Press, New York, pp 829–841.Google Scholar